sevelamer (Renagel, Genzyme, Renvela)
Jump to navigation
Jump to search
Introduction
calcium & aluminum-free phosphate-binder
Indications
- reduction of serum phosphorus in patient with end-stage renal disease
- renal osteodystrophy[3]
Contraindications
Dosage
- 2-4 tablets with meals
- adjust dose for target serum phosphorus of < 6 mg/dL
Tabs: 403 mg.
Renagel is hydrochloride, Renvela is carbonate salt
Pharmacokinetics
- not absorbed following oral administration
Adverse effects
Mechanism of action
- calcium & aluminum-free phosphate-binder within intestines
- cross-linked poly(allylamine hydrochloride)
- reduces cholesterol & LDL cholesterol
More general terms
Components
References
- ↑ Micromedex vol 102
- ↑ Prescriber's Letter 14(12): 2007 New Drug: Renvela (Sevelamer Carbonate) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=231206&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 3.0 3.1 Deprecated Reference